Tasaku Tsunoda

Q: What Schools Are Affiliated With Tasaku Tsunoda

Tasaku Tsunoda is affiliated with the following schools: University of Tokyo, Showa University, Wakayama Medical University, Kyoto University

Tasaku Tsunoda's AcademicInfluence.com Rankings

Tasaku Tsunoda

Communications

#2785

World Rank

#3963

Historical Rank

Linguistics

#744

World Rank

#966

Historical Rank

communications Degrees

Download Badge

Communications

Tasaku Tsunoda's Degrees

PhD Linguistics University of Tokyo
Masters Linguistics University of Tokyo
Bachelors Linguistics University of Tokyo

Why Is Tasaku Tsunoda Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Tsunoda Tasaku is a Japanese linguist, specializing in Australian Aboriginal languages. His interests embrace linguistic typology and endangered languages. Career Tsunoda was born in Akagi, Gumma Prefecture in 1946. On graduating from Tokyo University, Tsunoda moved to Monash University in Melbourne where he completed a master's and then a doctoral degree in linguistics. His choice of Melbourne for postgraduate work was partially influenced by the fact that the Monash campus was close to an athletic training camp run by the former world middle distance champion Herb Elliott. His supervisor for both his M.A. and PhD was Barry Blake.

(See a Problem?)

Tasaku Tsunoda's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis (2010) (143)
Vaccination with multiple peptides derived from novel cancer‐testis antigens can induce specific T‐cell responses and clinical responses in advanced esophageal cancer (2009) (134)
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens (2012) (122)
Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. (2003) (119)
Identification of human leukocyte antigen‐A24‐restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy (2007) (118)
Identification of a Novel Tumor-Associated Antigen, Cadherin 3/P-Cadherin, as a Possible Target for Immunotherapy of Pancreatic, Gastric, and Colorectal Cancers (2008) (105)
Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. (2005) (101)
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer (2010) (100)
HLA‐A2‐restricted CTL epitopes of a novel lung cancer‐associated cancer testis antigen, cell division cycle associated 1, can induce tumor‐reactive CTL (2008) (79)
Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay. (1992) (78)
Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer (2010) (76)
Detection of novel cancer‐testis antigen‐specific T‐cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma (2008) (75)
Inhibition of Tumor Growth with Antiangiogenic Cancer Vaccine Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 1 (2006) (69)
Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study (2015) (68)
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. (2012) (67)
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients (2014) (64)
Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. (2012) (63)
Ring Finger Protein 43 as a New Target for Cancer Immunotherapy (2004) (58)
Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas (2005) (56)
Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide–pulsed dendritic cells (2004) (54)
Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target. (2006) (54)
Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. (1991) (51)
Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4+ and CD8+ T-cell Epitopes: KIF20A-Specific CD4+ T-cell Immunity in Patients with Malignant Tumor (2013) (51)
Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53 (2001) (47)
Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo (2005) (44)
Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray (2006) (43)
The forkhead box M1 transcription factor as a candidate of target for anti‐cancer immunotherapy (2009) (42)
A novel tumor‐associated antigen, cell division cycle 45‐like can induce cytotoxic T‐lymphocytes reactive to tumor cells (2011) (38)
Identification of SPARC as a candidate target antigen for immunotherapy of various cancers (2010) (37)
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients (2018) (36)
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. (2016) (36)
In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients. (1992) (34)
Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors (2019) (31)
Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2 / neu: possible immunotherapy for colorectal carcinomas (2001) (29)
Identification of CDCA1‐derived long peptides bearing both CD4+ and CD8+ T‐cell epitopes: CDCA1‐specific CD4+ T‐cell immunity in cancer patients (2014) (28)
Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers (2003) (25)
Characterization of tumor-infiltrating immune cells in relation to microbiota in colorectal cancers (2019) (21)
Identification of HLA-A24-Restricted Novel T Cell Epitope Peptides Derived from P-Cadherin and Kinesin Family Member 20A (2012) (21)
Upregulated expression of angiogenesis genes and down regulation of cell cycle genes in human colorectal cancer tissue determined by cDNA macroarray. (2001) (21)
Augmentation of lymphokine-activated killer cell activity by lentinan. (1993) (20)
Defective autologous mixed lymphocyte reaction (AMLR) and killer activity generated in the AMLR in cancer patients (1992) (19)
In vitro generation of activated natural killer cells and cytotoxic macrophages with lentinan (2004) (17)
Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer (2018) (16)
Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease (2014) (16)
The promotive effect of interleukin 4 with interleukin 2 in the proliferation of tumor-infiltrating lymphocytes from patients with malignant tumor (1992) (16)
Differential gene expression profiles and identification of the genes relevant to clinicopathologic factors in colorectal cancer selected by cDNA array method in combination with principal component analysis. (2003) (16)
High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer (2020) (16)
Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors (2012) (16)
In vivo therapeutic effect of CDH3/P-cadherin-targeting radioimmunotherapy (2012) (15)
Functional and phenotypic analyses of interleukin 2-activated tumor-infiltrating lymphocytes (1990) (15)
Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms (2022) (15)
Cisplatin treatment renders tumor cells more susceptible to attack by lymphokine-activated killer cells. (1991) (14)
Phase I trial of OTS11101, an anti‐angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor (2013) (14)
Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil (2019) (14)
Generation of CD4+ cytotoxic T lymphocytes stimulated by immobilized anti‐CD3 monoclonal antibody and interleukin‐2 in cancer patients (1995) (14)
An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs (2016) (13)
Clinical evaluation of hepatic arterial infusion of low dose-CDDP and 5-FU with hyperthermotherapy: a preliminary study for liver metastases from esophageal and gastric cancer. (1999) (13)
Identification of an HLA-A2-Restricted Epitope Peptide Derived from Hypoxia-Inducible Protein 2 (HIG2) (2014) (13)
Modulation of multidrug resistance by cepharanthine in fresh human gastrointestinal tumor cells. (1997) (12)
Antitumor Effects of Interleukin‐2 Gene‐modified Fibroblasts in an Orthotopic Colon Cancer Model (1999) (12)
Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro. (1995) (12)
In vitro augmentation of antitumor effect in combination with CPT‐11 and CDDP for human colorectal cancer (2000) (12)
A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors (2020) (12)
Clinical and immunological evaluation of intraoperative radiation therapy for patients with unresectable pancreatic cancer (1992) (11)
P-glycoprotein-expressing tumor cells are resistance to anticancer drugs in human gastrointestinal cancer (2006) (11)
Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients. (2020) (11)
Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells. (1996) (10)
Expression of carcinoembryonic antigen in fresh human gastric cancer cells assessed by flow cytometry (1993) (10)
Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy (2021) (10)
Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination (2018) (9)
Synergistic effects of tamoxifen and cepharanthine for circumventing the multidrug resistance. (1996) (9)
Neutrophil functions and cytokine production in patients with gastric cancer. (2000) (9)
Role of interleukin-2 and interferon-γ in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432 (2004) (9)
Recent advances in active specific cancer vaccine treatment for colorectal cancer. (2012) (9)
In vitro augmentation of cytotoxic activity of peripheral blood lymphocytes and spleen cells of cancer patients by ubenimex. (1994) (9)
Analysis of ADAM12-Mediated Ephrin-A1 Cleavage and Its Biological Functions (2021) (8)
Guidance for peptide vaccines for the treatment of cancer (2014) (8)
Clonal and functional analysis for the augmentation of tumour-infiltrating lymphocytes by interleukin 4. (1996) (8)
Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet (2022) (8)
Impairment of autologous mixed lymphocyte reaction in the spleen and peripheral blood lymphocytes of patients with idiopathic portal hypertension (1990) (7)
Dose of Adenoviral Vectors Expressing Interleukin‐2 Plays an Important Role in Combined Gene Therapy with Cytosine Deaminase/5–Fluorocytosine: Preclinical Consideration (2002) (7)
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy (2021) (7)
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies (2021) (7)
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens (2012) (6)
Clinical significance of quantitative analysis of carcinoembryonic antigen assessed by flow cytometry in fresh human gastric cancer cells. (1995) (6)
Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan (2018) (6)
Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease (2022) (6)
Ubenimex treatment enhances the susceptibility of gastric cancer cell lines to lymphokine-activated killer cells. (1994) (6)
High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer (2020) (5)
Decreased Expression of α2,8 Sialyltransferase and Increased Expression of β1,4 N-Acetylgalactosaminyltransferase in Gastrointestinal Cancers (2002) (5)
Etoposide enhances the antitumor effects of cisplatin in gastric cancer cells. (1997) (5)
Successful immunochemotherapy for patients with malignant mesothelioma: Report of two cases (1998) (5)
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure (2021) (5)
Enhancement of tumor cell susceptibility to tumor-infiltrating lymphocytes by cisplatin (2005) (5)
In vitro antitumor effect of topoisomerase-I inhibitor, CPT-11, on freshly isolated human gastric and colorectal cancer. (1999) (5)
[Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer]. (2008) (4)
Future prospects for cancer immunotherapy - Strategies for ineffective cancers (2022) (4)
Tumor specific CTL therapy for advanced cancer and development for cancer vaccine. (1999) (4)
Clinical evaluation of chemotherapy under angiotensin II-induced hypertension in patients with advanced cancer. (1990) (4)
Non-T cell disturbance causes the suppression of the autologous mixed lymphocyte reaction in patients with gastric carcinoma. (1995) (4)
[Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes]. (1990) (4)
Fibronectin promotes the proliferation of cytotoxic T lymphocytes generated from cancer patients. (1996) (4)
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients (2020) (3)
Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer (2021) (3)
Phase II/III clinical trial with VEGFR2-epitope peptide and gemcitabine for patients with locally advanced, metastatic, or unresectable pancreatic cancer: Pegasus-PC study. (2013) (3)
Effect of Imatinib (STI571) on Metastatic Gastrointestinal Stromal Tumors: Report of a Case (2005) (3)
P-glycoprotein expression and chemosensitivity in highly purified fresh human gastrointestinal cancer cells. (1999) (3)
In vitro antitumor activity of TAS-103 against freshly-isolated human colorectal cancer. (2001) (2)
Identification of HLA-A 24-Restricted Novel T Cell Epitope Peptides Derived from P-Cadherin and Kinesin Family Member 20 A (2014) (2)
Development of anti-angiogenic cancer vaccine using epitope peptides derived from vascular endothelial growth factor receptor 1 (VEGFR1) (2006) (2)
A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer (2022) (2)
Superiority of [11C]methionine over [18F]deoxyglucose for PET Imaging of Multiple Cancer Types Due to the Methionine Addiction of Cancer (2023) (2)
[An epidemiological investigation for gram-positive coccus, especially MRSA, in Kinki area]. (1997) (2)
High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer (2020) (2)
Obesity Strongly Promotes Growth of Mouse MC38 Colon Cancer in an Orthotopic-syngeneic C57BL/6 Mouse Model (2022) (2)
Enhancement of tumor cell susceptibility to lymphokine-activated killer cells by treatment with the streptococcal preparation OK432 (1992) (2)
IN VITRO ANTITUMOR ACTIVITY OF A NEW PLATINUM ANALOGUE, NK 121 AGAINST FRESH HUMAN TUMOR CELLS AND ESTABLISlIED TUMOR CELL LINES BY SUCCINATE DEHYI)ROGENASE INHIBITION TEST (1990) (2)
Successful adoptive immunotherapy with OK432-inducible activated natural killer cells in tumor-bearing mice (1989) (2)
[New strategies in anti-tumor immunotherapy]. (2010) (2)
Endoscopic microwave coagulation therapy for villous adenoma of the duodenum-A case report (1991) (2)
[Development for a novel cancer vaccine]. (2004) (2)
Phase I clinical trial of cancer vaccine with five novel epitope peptides for patients with metastatic colorectal cancer (mCRC). (2011) (2)
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients (2018) (2)
SY1. building the foundation for investigator-initiated clinical trial (2012) (2)
Intraoperative radiation therapy for a patient with bulky disease of mesenteric non-Hodgkin’s lymphoma (2010) (2)
Peptide vaccines for cancers that express polypeptides DEPDC1 (2007) (1)
[Role of interleukin 2 and interferon gamma in induction of activated natural killer cells by the streptococcal preparation OK432]. (1989) (1)
The Sympathetic Nervous System Contributes to the Establishment of Pre-Metastatic Pulmonary Microenvironments (2022) (1)
Multidisciplinary treatment for gastric cancer patients by chemoimmunotherapy. (1999) (1)
Dynamic relationships among tumor, immune response, and microbiota (2017) (1)
[An epidemiological investigation for gram-positive coccus, especially PRSP, in Kinki area]. (1997) (1)
Abstract PD13-08: PD13-08 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/HER2–Negative Breast Cancer (BC) (2023) (1)
Suv39h2 as a target gene for cancer therapy (2012) (1)
ORAL THERAPY WITH AMPHOTERICIN B OF FUNGAL INFECTIONS IN SURGICAL ORAL THERAPY WITH AMPHOTERICIN B OF FUNGAL INFECTIONS IN SURGICAL (1990) (1)
An autoreactive T cell clone generated in the autologous mixed lymphocyte reaction in a patient with gastric carcinoma. (1993) (1)
Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer (2022) (1)
Decreased expression of alpha2,8 sialyltransferase and increased expression of beta1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers. (2002) (1)
Improvement of growth of Plasmodium falciparum fresh clinical isolates by using an established serum-free medium, GIT. (2000) (1)
Clinical efficacy of adoptive immunotherapy by IL-4 activated tumor-infiltrating lymphocytes in patients with advanced cancer (1997) (1)
1275 PHASE I CLINICAL TRIAL OF NOVEL CDCA1 DERIVED EPITOPE PEPTIDE VACCINE THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER (2011) (1)
[Gut Microbiota and Tumor Immune Microenvironment]. (2021) (1)
The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer (2021) (1)
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients with induced immune responses and a prolonged OS. (2014) (1)
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients (2014) (0)
Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction (2022) (0)
Peptide vaccines against cancers that express TTK-, URLC10- or KOC1 polypeptide (2006) (0)
[Therapeutic approach for colorectal cancer with topoisomerase as a molecular target]. (2003) (0)
Epitope peptides derived from karendothelvækstfaktorreceptor-1 as well as vaccines containing these peptides (2006) (0)
Successful adoptive immunotherapy with OK432-inducible activated NK cells on tumor-bearing mice (1988) (0)
Whole Genome Sequence Analysis of CTX-M-55 Producing Escherichia coli Isolates from Clinical Patients in Japan (2018) (0)
[Deep-seated fungal infection in surgery]. (1998) (0)
Abstract 4783: Identification of a novel TAA, SPARC, as a target for immunotherapy of various cancers (2010) (0)
Tomm34 peptides and vaccines containing these (2011) (0)
Peptide vaccines against cancers that express MPHOSPH1- or polypeptides DEPDC1 (2007) (0)
46 Genetic analysis of tumor cells derived from the stress of immune response for understanding of immunotherapy (2022) (0)
Oral Installation of Recombinant Methioninase-producing Escherichia coli into the Microbiome Inhibits Colon-cancer Growth in a Syngeneic Mouse Model (2022) (0)
Phase I Clinical Trial of Cancer Vaccine Combined with Chemotherapy Targeting both Tumor Antigen and Immune Tolerance Against Advanced Solid Tumors (2012) (0)
Immunological Modification of the Head and Neck Cancer Microenvironment by Short Chain Fatty Acids (2022) (0)
The Generation of CD4 Cytotoxic T Lymphocyte Augmented by Immobilized Anti-CD3 Antibody and Interleukin-2 (1993) (0)
Localization of Ca2+ binding proteins in lymphatic tissues. (1995) (0)
TOM34 gene associated with colon cancer (2006) (0)
expressed peptide vaccine for lung cancer, the polypeptide TTK (2006) (0)
Genes and polypeptides related to human colon cancers (2003) (0)
NKG2D-high T cells are able to be activated regardless of the level of NKG2D ligands expression (2022) (0)
[Augmentation of cytotoxic activity by combination with interleukin 2 and interferon gamma]. (1990) (0)
Title Clinical Evaluation of Chemotherapy under Angiotensin II-Induced Hypertension in Patients with Advanced Cancer (2016) (0)
[Severe surgical infection with no information in terms of bacteria]. (1996) (0)
KDR peptides and vaccines containing them. (2003) (0)
[Induction of activated natural killer cells by the streptococcal preparation OK432 (I). Induction from spleen cells of normal or tumor-bearing mouse primed in vivo and subsequently challenged in vitro with OK432]. (1989) (0)
Peptide vaccines for cancers that express polypeptides or DEPDC1 MPHOSPH1 (2007) (0)
Accumulation of genome-wide somatic loss of heterozygosity (LOH) as a prominent feature of advanced malignant soft tissue tumors and association with the BRCAness status, suppression of immune responses, and lower survival rates. (2021) (0)
Abstract 3883: High unbound plasma concentration of M-2, an active metabolite, is associated with shorter survival in patients with metastatic colorectal cancer who received regorafenib (2019) (0)
epitopes derived peptides 1 receptor vascular endothelial growth factor and vaccines containing these peptides (2006) (0)
Epitope peptides derived from the vascular endothelial growth factor receptor 1 and the vaccines containing these peptides (2006) (0)
Phase I and II Clinical Study of Cancer Vaccine Consisting of 5 Novel Epitope Peptides For Patients with Metastatic Colorectal Cancer (MCRC) (2012) (0)
Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer (2022) (0)
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study (2022) (0)
[A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer]. (2008) (0)
1107 POSTER Phase I Study of Multiple Peptides Vaccination in Patients With Advanced Bile Duct Cancer (2011) (0)
EFFECTS OF ANTIBACTERIAL AGENTS ON GENERAL RESPONSES OF BODY AFTER HIGHLY INVASIVE OPERATION (2000) (0)
Effect of intraoperative radiation therapy for pancreatic cancer on immunological parameters. (1990) (0)
Abstract #4159: Identification of novel tumor-associated antigens, Cadherin 3 (CDH3)/P-Cadherin and RAB6KIFL/KIF20A, as targets for anticancer immunotherapy of pancreatic cancer (2009) (0)
Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor (2023) (0)
Cdh3 peptide and drug comprising this (2008) (0)
The proliferation site of B-lymphocytes and the role of follicular dendritic cell in secondary lymphoid follicle of the tonsil. (1996) (0)
[Combination of adoptive immunotherapy and chemotherapy against advanced cancer with peritoneal dissemination]. (1990) (0)
Arsenic and new data. (1993) (0)
PHASE I CLINICAL TRIAL OF VACCINATION OF MPHOSPH1 AND DEPDC1 EPITOPE PEPTIDE VACCINE FOR PATIENTS WITH BLADDER CANCER (2009) (0)
In vitro antitumor activity of 4'-O-tetrahydropyranyladriamycin on human gastric cancer cells. (1996) (0)
Interleukin-4 inhibits lak and initial phase til activity via interleukin-2 receptor. (1995) (0)
Phase I clinical trial with VEGFR2-epitope peptide and gemcitabine for patients with advanced pancreatic cancer. (2009) (0)
Abstract 2146: High expression of Olfactomedin-4 correlates with chemoresistance and poor prognosis for pancreatic cancer (2019) (0)
Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors (2022) (0)
Peptide vaccine for colorectal cancer; an update (2011) (0)
peptide vaccines for cancers that express tumor associated antigens (2008) (0)
A Case of Cerebral Infarction During Treatment With Rivaroxaban for Venous Thromboembolism. (2020) (0)
Development of Hypoxia: Activated Cytotoxic Prodrug (2017) (0)
A triple-negative matrix-producing breast carcinoma is arrested by tumor-targeting Salmonella typhimurium A1-R in a PDOX model (2021) (0)
77 PHASE I CLINICAL TRIAL OF NOVEL HIG2 DERIVED EPITOPE PEPTIDE VACCINE TREATMENT FOR KIDNEY CANCER (2010) (0)
Synergy of Combining Methionine Restriction and Chemotherapy: The Disruptive Next Generation of Cancer Treatment (2023) (0)
A CASE OF AN APPENDICOASCENDING FISTULA DUE TO RETROCECAL APPENDICITIS WITH AML (2007) (0)
peptide vaccines derived from EphA4 (2008) (0)
Autologous mixed lymphocyte reaction and postoperative prognosis in patients with gastric carcinoma. (1996) (0)
Salmonella typhimurium A1-R Exquisitely Targets and Arrests a Matrix-producing Triple-negative Breast Carcinoma in a PDOX Model (2021) (0)
SQUAMOUS CELL CARCINOMA OF THE PANCREAS FOUND BY INVASION TO THE SPLEEN AND COLON (1994) (0)
Clinical effects of chemoimmunotherapy for patients with peritoneal carcinomatosis. (1997) (0)
HIG2- AND URLC10 epitope AND VACCINES THAT CONTAINS (2009) (0)
[Defective autologous mixed lymphocyte reaction (AMLR) in gastric cancer patients]. (1990) (0)
RETROPERITONEAL NON-HODGKIN'S LYMPHOMA AND TREATMENT WITH INTERFERON α AND CHOP-BLEOMYCIN (1988) (0)
Abstract 2834: Cancer testis antigens-specific CD4+ T-cell immunity augmented by CTL-epitopes vaccination in cancer patients. (2013) (0)
A CASE REPORT OF MINIMAL THYROID CANCER DIAGNOSED DUE TO BONE METASTASIS (1991) (0)
The expression of cytokines and their receptors in lymphoid tissues. (1995) (0)
Phase I trial of cancer vaccine with multiple peptides derived from novel onco-antigen and anti-angiogenic antigens for patients with advanced non-small cell lung cancer (NSCLC). (2012) (0)
Genes and proteins related to human colon cancer (2003) (0)
[Nasobiliary drainage for spontaneous bile peritonitis due to cholangiocarcinoma]. (1991) (0)
Date of Patent : ( 54 ) HIG 2 AND URLC 10 EPITOPE PEPTIDE AND VACCNES CONTAINING (2017) (0)
Successful adoptive immunotherapy with OK432-inducible activated natural killer cells in tumor-bearing mice. (1990) (0)
Peptide vaccines for lung cancers expressing TTK polypeptides, URLC10 or KOC1 (2006) (0)
Establishment for big data base of Microbiota closely related to diseases - Showa U bank - (2018) (0)
Case of Imatinib Susceptibility to CYP3A4-Mediated Drug-Drug Interactions in a Patient With Gastrointestinal Stromal Tumor. (2022) (0)
Immunological effects of inosine, a metabolite from gut microbiota, in the tumor microenvironment (2022) (0)
NHBB EPITOPE PEPTIDES AND VACCNES CONTAINING THE SAME (2017) (0)
Tumor immunity and immunosurveillance (PP-093) (2010) (0)
NEIL3 peptides and vaccines that include the same (2010) (0)
Expression of Adhesion Molecules on Human Follicular Dendritic Cells(FDCs) in Germinal Centeres, with Special Reference to Fibronectin-and Laminin-Receptors. (1995) (0)
Augmentation of cytotoxic activity by combination with interleukin 2 and interferon gamma. (1991) (0)
Cisplatin modulates tumor cell susceptibility to tumor-infiltrating lymphocytes in vivo. (1997) (0)
Gut microbiota opens the future of cancer immunotherapy (2019) (0)
Agranulocytosis During Treatment With Sulfamethoxazole-Trimethoprim and a Proton Pump Inhibitor. (2019) (0)
MPHOSPH1 peptides and vaccines that include the same (2012) (0)
Epitope peptide RAB6KIFL / KIF20A and vaccines containing the same (2009) (0)
P48-8 A case of primary lung cancer that led to the diagnosis of SMARCA4-deficient thoracic sarcoid tumor by oncogene panel testing (2021) (0)
Gut microbiota associate with recurrence of cancer after surgery in colorectal cancer patients. (2022) (0)

This paper list is powered by the following services:

Other Resources About Tasaku Tsunoda

en.wikipedia.org

What Schools Are Affiliated With Tasaku Tsunoda?

Tasaku Tsunoda is affiliated with the following schools:

Tasaku Tsunoda's Academic­Influence.com Rankings